CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jun. 27, 2015	Jun. 28, 2014
Cash Flows from Operating Activities:
Net loss	$ (267)	$ (3,649)
Non-cash items:
Depreciation and amortization	22,255	20,511
Amortization of financing costs	222	347
Stock compensation expense	3,164	3,489
(Gain)/loss on sale of property, plant and equipment	(25)	414
Unrealized (loss)/gain from hedging activities	(186)	104
Change in fair value of contingent consideration	83	224
Asset write-down	0	261
Change in operating assets and liabilities:
Change in accounts receivable, net	6,574	7,918
Change in inventories	(718)	(9,569)
Change in prepaid income taxes	(369)	(313)
Change in other assets and other liabilities	3,699	(589)
Tax benefit of exercise of stock options	0	285
Change in accounts payable and accrued expenses	(25,182)	(5,695)
Net cash provided by operating activities	9,250	13,738
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(24,246)	(37,085)
Proceeds from sale of property, plant and equipment	116	64
Other acquisitions and investments	3,000	0
Net cash used in investing activities	(27,130)	(37,021)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(276)	(254)
Net increase in short-term loans	4,380	1,687
Repayment of term loan borrowings	0	(8,531)
Proceeds from employee stock purchase plan	2,263	2,530
Proceeds from exercise of stock options	2,893	2,223
Share repurchases	(39,032)	(26,466)
Net cash used in financing activities	(29,772)	(28,811)
Effect of exchange rates on cash and cash equivalents	(806)	(432)
Net Change in Cash and Cash Equivalents	(48,458)	(52,526)
Cash and Cash Equivalents at Beginning of Period	160,662	192,469
Cash and Cash Equivalents at End of Period	112,204	139,943
Supplemental Disclosures of Cash Flow Information:
Interest paid	2,068	2,011
Income taxes paid	1,625	2,097
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 2,925	$ 2,443